Evidence map›Paper›PMID 39741348›Full record

ArticleClinical epigenetics2024

Altered chromatin landscape and 3D interactions associated with primary constitutional MLH1 epimutations.

Paula Climent-Cantó, Marc Subirana-Granés, Mireia Ramos-Rodríguez, Estela Dámaso, Fátima Marín, Covadonga Vara, Beatriz Pérez-González, Helena Raurell, Elisabet Munté, José Luis Soto and 7 more

Abstract read
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Paula Climent-CantóHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Marc Subirana-GranésDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003, Barcelona, Spain.
Mireia Ramos-RodríguezDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003, Barcelona, Spain.
Estela DámasoHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Fátima MarínHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Covadonga VaraHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Beatriz Pérez-GonzálezDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003, Barcelona, Spain.
Helena RaurellDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003, Barcelona, Spain.
Elisabet MuntéHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
José Luis SotoMolecular Genetics Laboratory, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), University Hospital of Elche, 03203, Elche, Alicante, Spain.
Ángel AlonsoGenomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008, Pamplona, Spain.
GiWon ShinDepartment of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA.
Hanlee JiDepartment of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA.
Megan HitchinsDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Gabriel CapelláHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. gcapella@idibell.cat.
Lorenzo PasqualiDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003, Barcelona, Spain. lorenzo.pasquali@upf.edu.
Marta PinedaHereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. mpineda@iconcologia.net.

Funding

The mechanistic basis for constitutional MLH1 methylation (epimutation)R01CA218342 · NCI · CEDARS-SINAI MEDICAL CENTER · PI HITCHINS, MEGAN P · 2019 to 2022
$1.9M
NCI NIH HHS R01 CA218342
6 · The paper itself

Abstract

backgroundLynch syndrome (LS), characterised by an increased risk for cancer, is mainly caused by germline pathogenic variants affecting a mismatch repair gene (MLH1, MSH2, MSH6, PMS2). Occasionally, LS may be caused by constitutional MLH1 epimutation (CME) characterised by soma-wide methylation of one allele of the MLH1 promoter. Most of these are "primary" epimutations, arising de novo without any apparent underlying cis-genetic cause, and are reversible between generations. We aimed to characterise genetic and gene regulatory changes associated with primary CME to elucidate possible underlying molecular mechanisms.

methodsFour carriers of a primary CME and three non-methylated relatives carrying the same genetic haplotype were included. Genetic alterations were sought using linked-read WGS in blood DNA. Transcriptome (RNA-seq), chromatin landscape (ATAC-seq, H3K27ac CUT&Tag) and 3D chromatin interactions (UMI-4C) were studied in lymphoblastoid cell lines. The MLH1 promoter SNP (c.-93G > A, rs1800734) was used as a reporter in heterozygotes to assess allele-specific chromatin conformation states.

resultsMLH1 epimutant alleles presented a closed chromatin conformation and decreased levels of H3K27ac, as compared to the unmethylated allele. Moreover, the epimutant MLH1 promoter exhibited differential 3D chromatin contacts, including lost and gained interactions with distal regulatory elements. Of note, rare genetic alterations potentially affecting transcription factor binding sites were found in the promoter-contacting region of CME carriers.

conclusionsPrimary CMEs present allele-specific differential interaction patterns with neighbouring genes and regulatory elements. The role of the identified cis-regulatory regions in the molecular mechanism underlying the origin and maintenance of CME requires further investigation.

Indexed as

ChromatinColorectal Neoplasms, Hereditary NonpolyposisDNA MethylationMutL Protein Homolog 1Promoter Regions, GeneticAdultAllelesEpigenesis, GeneticFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideChromatinMLH1 protein, humanMutL Protein Homolog 13D interactionsChromatin structureCis-regulatory regionsConstitutional MLH1 epimutationLynch syndromeMLH1 promoter methylation

Identifiers

PMID39741348
PMCPMC11686911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.